The Technical Analyst
Aeterna Zentaris Inc [AEZS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aeterna Zentaris Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.01% $1.960
America/New_York / 25 apr 2024 @ 09:34
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.52 mill |
| EPS: | -3.41 |
| P/E: | -0.570 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 4.86 mill |
| Avg Daily Volume: | 0.0159 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.570 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.570 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.818 - 2.10 ( +/- 7.24%) |
| ATR Model: 14 days |
Forecast:
11:14 - $1.975
Live Trading Signals (every 1 min)
Forecast
1: 09:44 - $1.960
Forecast 2: 10:34 - $1.975
Forecast 3: 11:14 - $1.975
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $1.960 (-1.01% ) |
| Volume | 0.0004 mill |
| Avg. Vol. | 0.0159 mill |
| % of Avg. Vol | 2.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AEZS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AEZS
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Latest Press Releases
2024-03-28 07:55:00 - Press Release
Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Toronto and edmonton, march 28, 2024 (globe newswire) -- aeterna zentaris inc. (nasdaq: aezs) (tsx: aezs) ("aeterna") and ceapro inc. (tsx-v: czo; otcqx: crpof) (“ceapro”) are pleased to announce that the court of king's bench of alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of ceapro and aeterna in an all-stock merger of equals transaction (the “transaction”).
2024-03-27 08:05:00 - Press Release
Aeterna Zentaris Reports Fourth Quarter And Full Year 2023 Financial Results And Announces Completion Of Enrollment In Ongoing Pivotal Detect-trial For The Diagnosis Of Childhood-onset Growth Hormone Deficiency
- company confirms successful completion of enrollment in the pivotal detect phase 3 trial
2024-03-12 14:10:00 - Press Release
Aeterna Zentaris And Ceapro Merger Approved By Securityholders At Special Meetings
Toronto and edmonton, march 12, 2024 (globe newswire) -- aeterna zentaris inc. (nasdaq: aezs) (tsx: aezs) (“aeterna”) and ceapro inc. (tsx-v: czo; otcqx: crpof) (“ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “transaction”) at their respective special meetings held today. the specific voting results were as follows:
2024-02-26 07:30:00 - Press Release
Leading Independent Proxy Advisory Firm Iss Recommends Aeterna Zentaris And Ceapro Securityholders Vote For The Arrangement Agreement To Approve The Merger Of Equals To Create A Diversified Biopharmaceutical Company
Toronto and edmonton, feb. 26, 2024 (globe newswire) -- aeterna zentaris inc. (nasdaq: aezs) (tsx: aezs) (“aeterna zentaris”) and ceapro inc. (tsxv: czo) (otcqx: crpof) (“ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent proxy advisor institutional shareholder services inc. ("iss") recommended that both companies' securityholders vote for the all-stock merger of equals transaction (the “transaction”) pursuant to the terms announced on december 14, 2023.
2024-02-15 17:50:00 - Press Release
Aeterna Zentaris Issues Letter To Shareholders And Management Proxy Circular Ahead Of Special Meeting Of Shareholders To Approve Merger Of Equals With Ceapro
Toronto, feb. 15, 2024 (globe newswire) -- aeterna zentaris inc. (nasdaq: aezs) (tsx: aezs) ("aeterna") today announced that it has issued a letter to shareholders and management proxy circular ahead of its special meeting of shareholders to approve its merger of equals transaction with ceapro inc. (tsxv: czo) (otcqx: crpof) ("ceapro").
Latest News
2024-03-27 10:26:14 - Zacks Investment Research
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $0.84 per share a year ago.
2023-03-23 10:40:21 - Zacks Investment Research
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-02-07 11:19:16 - Zacks Investment Research
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
2023-01-10 08:05:00 - GlobeNewsWire
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
2022-05-18 08:00:00 - GlobeNewsWire
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
2022-02-07 08:05:00 - GlobeNewsWire
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually, February 14-17, 2022.
2022-01-20 08:05:00 - GlobeNewsWire
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
2022-01-05 08:36:00 - GlobeNewsWire
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright Bio C onnect Conference taking place January 10-13, 2022.
2021-10-01 12:46:52 - InvestorPlace
3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today
A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today appeared first on InvestorPlace.
2021-09-08 08:00:00 - GlobeNewsWire
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23 rd Annual Global Investment Conference taking place September 13-15, 2021.